NeoGenomics, a Fort Myers cancer lab, will pay $9.8 million to settle a federal investigation
NeoGenomics, the cancer testing company headquartered in Fort Myers, said on July 20 that it had settled a federal investigation into some of its past consulting arrangements. The company will pay $9,813,260, plus interest at 4.250 percent a year from January 16, 2026, under an agreement with the U.S. Department of Justice acting on behalf of the Office of Inspector General of the Department of Health and Human Services. The settlement was disclosed in a company press release and a filing with the Securities and Exchange Commission the same day.
The matter is an old one. NeoGenomics reported in its release that it had voluntarily disclosed the underlying issue to the inspector general in November 2021, after an internal review of how it had provided consulting services to health care providers under a program the company calls its Laboratory Collaboration Initiative. The settlement resolves the government's investigation of those arrangements. It states that the payment is neither an admission of liability by the company nor a concession by the United States that its claims lack merit, which is standard language for a negotiated civil resolution of this kind.
The number that matters for the company is that the settlement came in under what it had set aside. NeoGenomics had previously disclosed a reserve of $11.2 million for potential damages and liabilities tied to the investigation, so a payment near $9.8 million falls below that figure. Tony Zook, the chief executive, said the company was pleased to resolve the legacy matter and that doing so would let it keep moving forward on advancing personalized cancer care, according to the release.
The local weight of the story is that NeoGenomics is a Fort Myers company, one of the region's few publicly traded employers, and this is the resolution of a years-long federal question rather than the start of one. The figures here come from the company's own settlement announcement and its SEC filing, both linked below, and not from a secondhand summary of them.
